GENMAB A/S
GMAB GNMSFCIK 0001434265 · Pharmaceutical Preparations · Nasdaq, OTC
Revenue (TTM)
9.04B
+19.2% YoY
FY Dec 2025
Net Income (TTM)
3.77B
−15.0% YoY
FY Dec 2025
EPS Diluted (TTM)
57.49
−12.3% YoY
FY Dec 2025
Gross Margin
97.4%
FY Dec 2025
Operating Margin
36.6%
FY Dec 2025
Net Margin
41.7%
FY Dec 2025
Free Cash Flow (TTM)
—
FY Dec 2025
Cash
1.72B
FY Dec 2025
Total Debt
—
FY Dec 2025
Shares Outstanding
—
FY Dec 2025